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Background
A T Li sa na g g r e s s i v eT - c e l lm a l i g n a n c yc a u s e db yt h e
virus HTLV-1 with a very poor outcome. ATL, and is
characterized by its cell surface expression of CC che-
mokine receptor 4 (CCR4), to which KW-0761, a defu-
cosylated, humanized antibody with enhanced antibody-
dependent cellular cytotoxicity (ADCC), binds. In a
phase I study of KW-0761 in 13 patients (pts) with
CCR4-positive relapsed ATL, encouraging efficacy of
KW-0761 was observed (ORR of 31%; 2CRs and 2PRs,
ref. 3). Here, we report the result of a pivotal phase II
study of KW-0761 in pts with CCR4-positive relapsed
ATL.
Results
A multicenter phase II study of KW-0761 has been con-
ducted for pts with CCR4 positive, relapsed aggressive
ATL with the primary endpoint being overall response
rate (ORR). Pts were planned to receive intravenous
infusions of KW-0761 at 1.0 mg/kg once a week for 8
weeks. Twenty-eight pts were enrolled, among whom,
27 had at least one infusion of KW-0761. Most frequent
adverse events (AEs) were mild to moderate in severity.
The most frequent drug-related AEs were lymphopenia,
acute infusion reaction, fever, skin rash, chill, thrombo-
cytopenia and neutropenia. Among the 26 pts evaluable
for efficacy, the ORR was 50% with 8 CRs and 5 PRs
with response rates in each affected lesion being 100%
(13/13) for peripheral blood, 63% (5/8) for skin, and
25% (3/12) for lymph node disease, respectively.
Updated data including progression-free survival and
overall survival, will be presented at the meeting with
additional results of prognosis in the phase I study.
Author details
1Hematology, Imamura Bun-in Hospital, Kagoshima, Kagoshima, 890-0064,
Japan.
2Hematology and Stem Cell Transplantation, National Cancer Center
Hospital, Japan.
3Hematology and Cell Therapy, Aichi Cancer Center, Japan.
4Medical Oncology and Immunology, Nagoya City University, Japan.
5Hematology, National Kyushu Cancer Center, Japan.
6Hematology and
Molecular Medicine, Nagasaki University, Japan.
7Hematology and
Immunology, Kagoshima University, Kagoshima, Kagoshima, 890-0064, Japan.
8Internal Medicine, Japanese Red Cross Nagasaki Genbaku Hospital, Japan.
Published: 6 June 2011
doi:10.1186/1742-4690-8-S1-A40
Cite this article as: Utsunomiya et al.: Promising results of an anti-CCR4
antibody, KW-0761, for relapsed Adult T-Cell Leukemia-Lymphoma
(ATL). Retrovirology 2011 8(Suppl 1):A40.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
* Correspondence: autsunomiya@jiaikai.jp
1Hematology, Imamura Bun-in Hospital, Kagoshima, Kagoshima, 890-0064,
Japan
Full list of author information is available at the end of the article
Utsunomiya et al. Retrovirology 2011, 8(Suppl 1):A40
http://www.retrovirology.com/content/8/S1/A40
© 2011 Utsunomiya et al; licensee BioMed Central Ltd. This is an open access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.